[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cytoreductive-surgery\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cytoreductive-surgery":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,44,73,99,123],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100629727","impact-of-an-omega-3-enriched-oral-nutritional-supplement-on-improving-surgical-outcomes-in-patients-with-peritoneal-carcinomatosis-undergoing-cytoreductive-surgery-100629727",false,"NCT07478432","Impact of an Omega-3 Enriched Oral Nutritional Supplement on Improving Surgical Outcomes in Patients With Peritoneal Carcinomatosis Undergoing Cytoreductive Surgery","Impact of an Omega-3 Enriched Oral Nutritional Supplement on Improving Surgical Outcomes in Patients With Peritoneal Carcinomatosis Undergoing Cytoreductive Surgery: A Pilot, Prospective, Randomized, Double-Blind, Controlled Study","OMNI","Inclusion Criteria:\n\n* Age \\> 18 years\n* Diagnosis of peritoneal carcinomatosis from a non-gynecological primary neoplasm\n* Patients who must undergo cytoreductive surgery and HIPEC\n* Signed informed consent form\n\nExclusion Criteria:\n\n* Patients with an enterocutaneous fistula\n* Patients with known food allergies\n* Age \\\u003C 18 years\n* Patients with severe organ damage (e.g., kidney failure, liver failure)\n* Refusal to sign the informed consent form","ALL","18 Years",{"count":20,"type":21},28,"ESTIMATED","INTERVENTIONAL",[24],"NA","The OMNI study is a clinical trial investigating whether a nutritional supplement with added Omega-3 fatty acids can improve surgical outcomes for patients with peritoneal carcinomatosis. Peritoneal carcinomatosis is a type of cancer that affects the abdominal lining and often requires complex and extensive surgery called cytoreductive surgery (CRS). This procedure is associated with a high risk of postoperative complications, such as infections and long hospital stays. Omega-3 fatty acids are known for their anti-inflammatory and immune-modulating properties.\n\nThe study's main goal is to see if a 21-day regimen of a pre-operative Omega-3 enriched oral nutritional supplement (ONS) can reduce postoperative complications, as measured by the Clavien-Dindo classification.\n\nWho can participate?\n\nThe study is recruiting patients over 18 years old who have been diagnosed with non-gynecological peritoneal carcinomatosis and are scheduled to undergo cytoreductive surgery and HIPEC (hyperthermic intraperitoneal chemotherapy).\n\nWhat does participating involve?\n\nUpon joining the study, participants will be randomly assigned to one of two groups:\n\n* Intervention Group: Participants will receive an Omega-3 enriched nutritional supplement called Fortimel Forticare.\n* Control Group: Participants will receive a standard nutritional supplement called Fortimel Compact Protein.\n\nBoth groups will be asked to consume two bottles of their assigned supplement per day for 21 days before the scheduled surgery.\n\nWhat will be measured?\n\nThroughout the study, the investigators will perform various assessments to monitor participant health and recovery:\n\n* Before and after surgery: The investigators will take body measurements, conduct a bioimpedance analysis (BIA) to check body composition, and perform a Hand Grip test to measure muscle strength. The investigators will also collect blood and stool samples.\n* During surgery: The investigators will collect tissue samples to study the tumor environment.\n* After surgery: The investigators will track patient recovery, including the length of the hospital stay and any complications that may occur. The investigators will also continue to monitor certain markers in the patients' blood.\n\nThe study is expected to enroll a total of 28 patients.",[27,28,29,30],"Peritoneal Carcinosis","Peritoneal Metastases","HIPEC","Cytoreductive Surgery","NOT_YET_RECRUITING","2026-03-13",{"date":34,"type":35},"2026-03-17","ACTUAL",{"date":37,"type":21},"2026-04",{"date":39,"type":21},"2028-10",{"name":41,"class":42},"Catholic University of the Sacred Heart","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":51,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":52,"targetDuration":54,"studyType":55,"phases":4,"briefSummary":56,"conditions":57,"keywords":59,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":43},"100627657","ventral-hernias-following-cytoreductive-surgery--incidence-risk-factors-and-surgical-management-100627657","NCT07451483","Ventral Hernias Following Cytoreductive Surgery : Incidence, Risk Factors and Surgical Management.","Incidence, Risk Factors and Surgical Management of Incisional Hernias Following Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy: A Retrospective Monocentric Cohort Study","Inclusion Criteria:\n\n* All adult patients (≥18 years) who underwent CRS +\u002F- HIPEC for PMP, colorectal and ovarian PC between 01 January 2010 and 31 December 2024.\n\nExclusion Criteria:\n\n* Patients with a prior history of ventral hernia at the planned incision site.\n* Patients undergoing CRS +\u002F- HIPEC for primary cancer other than PMP, colorectal and ovarian PC.\n* Patients with incomplete medical records preventing data extraction.\n* Patients lost to follow-up within one year of surgery.",true,{"count":53,"type":21},500,"1 Year","OBSERVATIONAL","Cytoreductive surgery (CRS), with or without hyperthermic intraperitoneal chemotherapy (HIPEC), is currently the standard treatment for advanced peritoneal tumors, including pseudomyxoma peritonei (PMP), colorectal, and ovarian peritoneal carcinomatosis. This complex surgical approach involves extensive resections to remove all visible tumor deposits, often followed by heated intraperitoneal chemotherapy to target residual microscopic disease. While CRS ± HIPEC has been shown to improve survival, it is associated with significant postoperative morbidity, particularly affecting the abdominal wall. One of the most frequent and clinically relevant complications is the development of ventral (incisional) hernias, which can reduce quality of life, limit physical activity, and sometimes require additional surgical repair.\n\nThe incidence, risk factors, and optimal management of ventral hernias after CRS ± HIPEC remain incompletely defined. Reported incidences vary widely, likely due to differences in surgical techniques, patient populations, definitions of hernia, and follow-up duration. Known contributing factors include extensive laparotomies, multiple resections, tissue fragility induced by hyperthermic chemotherapy, and patient-specific factors such as age and body mass index. Additionally, management strategies for ventral hernias are heterogeneous, ranging from direct fascial closure to reinforcement with synthetic or biological meshes, using different surgical approaches (onlay or sublay), with limited evidence in oncologic settings.\n\nThis single-center retrospective observational study at the Institut Jules Bordet aims to provide a comprehensive analysis of ventral hernia occurrence, risk factors, and management following CRS ± HIPEC. Adult patients who underwent CRS ± HIPEC for PMP, colorectal, or ovarian peritoneal carcinomatosis between January 1, 2010, and December 31, 2024, were included. Patients with prior ventral hernias, incomplete follow-up (\\\u003C12 months), missing data, or interrupted CRS due to extensive disease were excluded. Hernias were identified via clinical examination and imaging studies (CT or MRI), and classified as early (\\\u003C12 months) or late (\\>12 months) postoperative events. Patients were categorized according to the presence or absence of ventral hernias at the incision site.\n\nThe primary objective of the study is to determine the incidence of incisional hernias following CRS ± HIPEC. Secondary objectives include (1) identification of patient-related and surgical risk factors associated with hernia development, and (2) analysis of institutional surgical management strategies, including type of repair and timing of intervention. Data were collected retrospectively from medical records, and statistical analyses include descriptive statistics, survival analysis, and univariate and multivariate regression to identify independent risk factors for hernia development.\n\nThis study is expected to provide valuable insights into the epidemiology, risk factors, and management of ventral hernias in patients undergoing CRS ± HIPEC, contributing to improved postoperative care, informed surgical planning, and potentially guiding institutional and international recommendations for hernia prevention and repair in this high-risk population.\n\nThis study aims to provide a comprehensive understanding of the occurrence, risk factors, and management of ventral hernias in patients undergoing CRS ± HIPEC, which may help guide surgical practice and improve postoperative outcomes.",[58,30],"Ventral Hernias",[58,30,29,60,61,62],"Surgical Management of Ventral Hernias","Peritoneal Metastasis of Ovarian or Colorectal Cancer, Pseudomyxoma Peritonei","Peritoneal Carcinomatosis","RECRUITING","2026-02-28",{"date":66,"type":35},"2026-03-05",{"date":68,"type":35},"2026-01-20",{"date":70,"type":21},"2026-03",{"name":72,"class":42},"Jules Bordet Institute",{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":80,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":82,"conditions":83,"keywords":86,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":43},"100586964","hipec-surgery-and-hemodynamics-100586964","NCT06922227","HIPEC Surgery and Hemodynamics","Perioperative Hemodynamic and Respiratory Changes During Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Combined With Cytoreductive Surgery","Inclusion Criteria:\n\n* ≥18 years old Patients planned to undergo cytoreductive surgery with hyperthermic intraperitoneal chemotherapy\n* ASA II-III-IV physical class\n\nExclusion Criteria:\n\n* \\\u003C18 years\n* Emergency cases",{"count":81,"type":21},15,"Hyperthermic Intraperitoneal Chemotherapy (HIPEC) involves the intraoperative administration of heated chemotherapeutic agents into the abdominal cavity following cytoreductive surgery (CRS). The increasing use of CRS combined with HIPEC has introduced certain procedural and physiological considerations that distinguish it from other surgical interventions, posing unique challenges for researchers and clinicians alike.\n\nDespite advancements in surgical and anesthetic techniques, this combined approach is frequently associated with significant hemodynamic instability, coagulation abnormalities, respiratory complications, and nutritional imbalances.\n\nThe study aims to contribute to the existing body of knowledge by examining the physiological alterations induced by HIPEC, thereby offering practical insights and guidance for investigators involved in the management and study of this complex therapeutic modality.",[84,30,85],"Hemodynamics","Hyperthermic Intraperitoneal Chemotherapy (HIPEC)",[87,88,84],"HİPEC","cytoreductive surgery","2025-04-10",{"date":91,"type":35},"2025-04-13",{"date":93,"type":21},"2025-04-01",{"date":95,"type":21},"2025-07-15",{"name":97,"class":98},"Miray Gözde Özdemir","OTHER_GOV",{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":4,"eligibilityCriteria":105,"healthyVolunteers":11,"sex":17,"minAge":106,"maxAge":4,"enrollmentInfo":107,"targetDuration":4,"studyType":22,"phases":109,"briefSummary":110,"conditions":111,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":43},"100485177","quadratus-lumborum-block-after-cytoreductive-surgery-and-hyperthermic-intra-peritoneal-chemotherapy-100485177","NCT05597683","Quadratus Lumborum Block After Cytoreductive Surgery and Hyperthermic Intra-peritoneal Chemotherapy","Quadratus Lumborum Block for Analgesia After Cytoreductive Surgery and Hyperthermic Intra-peritoneal Chemotherapy (CRS and HIPEC): a Double-blind Randomized Controlled Trial","Inclusion Criteria:\n\n\\- Adult patients who are scheduled to undergo cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy (CRS and HIPEC)\n\nExclusion Criteria:\n\n1. Allergy to local anesthetics or fentanyl\n2. Chronic pain\n3. Drug abuse\n4. Patients who are unable to use patient-controlled analgesia\n5. Skin infection at site for quadratus lomborum block\n6. pregnant or breatfeeding women\n7. Patients who are unable to communicate","19 Years",{"count":108,"type":21},50,[24],"This study aims to assess whether transmusculr quadratus lomborum block (QL block) can reduce postoperative pain after cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy (CRS and HIPEC). Patients will be randomly assigned to either QL block group or control group. Ultrasound-guided bilateral transmuscular quadratus lomborum block will be performed in QL block group using 0.375% ropivacaine. Multimodal analgesic regimen including acetaminophen, nonsteroidal antiinflammatory drugs (NSAIDs), and rescue opioids will be used in every patient. Primary outcome is opioid consumption for 24 hours after surgery. Secondary outcomes included pain scores, time to first rescue analgesics, quality of recovery score, length of hospital stay.",[30,112,113],"Hyperthermic Intra-peritoneal Chemotherapy","Peritoneal Cancer","2024-08-14",{"date":116,"type":35},"2024-08-15",{"date":118,"type":35},"2022-11-15",{"date":120,"type":21},"2025-01-10",{"name":122,"class":42},"Gangnam Severance Hospital",{"id":124,"slug":125,"hasResults":11,"nctId":126,"briefTitle":127,"officialTitle":128,"acronym":4,"eligibilityCriteria":129,"healthyVolunteers":11,"sex":130,"minAge":18,"maxAge":131,"enrollmentInfo":132,"targetDuration":4,"studyType":22,"phases":134,"briefSummary":135,"conditions":136,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":137,"lastUpdatePostDateStruct":138,"startDateStruct":140,"completionDateStruct":141,"leadSponsor":143,"locationsCount":145},"100487907","cytoreductive-surgery-in-platinum-resistant-recurrent-ovarian-cancer-100487907","NCT05633199","Cytoreductive Surgery in Platinum-resistant Recurrent Ovarian Cancer","Cytoreductive Surgery in Platinum-resistant Recurrent Ovarian Cancer：a Randomized Controlled Study","Inclusion Criteria:\n\n1. Patients with diagnosis of epithelial ovarian carcinoma, peritoneal carcinoma, or fallopian tube carcinoma within 3 lines recurrence;\n2. Recurrence occurred within 6 months since platinum-based chemotherapy;\n3. R0 ideal debulking in initial surgery; PET-CT indicate the recurrence lesion is almost in abdominal cavity, which is isolated and not exceed 5 sites, and the ascites is less than 500ml;\n4. ECOG\u002FWHO Performance score of 0 to 1;\n5. Hematology function: Leukocyte≥ 3,5x10⁹\u002FL, neutrophil≥ 1,5x10⁹\u002FL, platelets ≥ 100x10⁹\u002FL;\n6. No Renal insufficiency: serum creatinine \\\u003C 1,5 time the normal limit, creatinine clearance \\> 60 mL\u002Fmin;\n7. No hepatic failure: bilirubin ≤ 1,5 time the Normal limit;\n8. Patients with good compliance;\n9. Patients having read, signed and dated Informed consent before any study procedure.\n\nExclusion Criteria:\n\n1. Platinum-refractory\u002Funcontrolled epithelial ovarian cancer;\n2. Mucous carcinoma or low-grade serous carcinoma;\n3. Suffering from other malignant tumors that have not achieved complete remission in the past 2 years;\n4. Patients have received abdominal or pelvic radiotherapy;\n5. General conditions cannot tolerate cytoreduction;\n6. Severe hypersensitivity reactions (≥ grade 3) to paclitaxel or platinum and\u002For any of its excipients;\n7. Unable or unwilling to sign the informed consent form;\n8. Patients judged by the investigator to be unlikely to follow the research steps, restrictions and requirements.","FEMALE","70 Years",{"count":133,"type":21},140,[24],"This novel study was specifically designed for platinum-resistant recurrent ovarian cancers with PFI\\\u003C6 months and aimed to compare prognosis of patients who received cytoreductive surgery followed by chemotherapy versus chemotherapy alone.",[30],"2022-11-30",{"date":139,"type":35},"2022-12-01",{"date":139,"type":21},{"date":142,"type":21},"2028-01-01",{"name":144,"class":42},"Women's Hospital School Of Medicine Zhejiang University",2]